Syschem (India) Ltd (531173)

Healthcare · Pharmaceuticals · NSE · Updated 2 September 2026

By StockFin Research Team • AI-Assisted Analysis • Source: BSE/NSE Filings

₹31.15 ↓ 45.63% (1Y)

🎯 Key Takeaways

Syschem (India) Ltd is in a turnaround phase marked by financial volatility and governance transition. The company swung from profitability in Q3FY26 to a loss in Q1FY27, driven by margin compression and operational headwinds, while simultaneously replacing its statutory auditor due to regulatory non-compliance.
Revenue declined 50.2% QoQ to ₹109 in Q1FY27.
⚠️ Operational volatility in core pharma intermediates business, with margins and profitability swinging quarter-on-quarter.

Market Cap

₹167

P/E Ratio

20.9

P/B Ratio

1.83

ROE

6.7%

ROCE

15.8%

Debt/Equity

0.00

Promoter

60.1%

✨ Ask AI About 531173 📊 Interactive Charts

📖 The Story

Syschem (India) Ltd is in a turnaround phase marked by financial volatility and governance transition. The company swung from profitability in Q3FY26 to a loss in Q1FY27, driven by margin compression and operational headwinds, while simultaneously replacing its statutory auditor due to regulatory non-compliance. Despite a strong balance sheet with zero debt and growing equity, recent operational performance raises concerns about near-term sustainability.

📰 What's Happening

In Q1FY27, Syschem reported a 50% revenue decline to ₹109 crore and a loss of ₹2 crore, reversing from ₹2 crore profit and ₹0.44 EPS in the prior quarter. Management attributed the deterioration to soft demand conditions and pricing pressure in its pharmaceutical intermediates business. Concurrently, the company announced the resignation of its statutory auditor, STAV & Co., effective 31 August 2026, citing the expiry of its Peer Review Certificate. The resignation, tied to regulatory non-renewal rather than performance issues, signals potential governance and compliance scrutiny. Management confirmed no other reasons for the exit and initiated a search for a new auditor, but the timing adds uncertainty ahead of the next financial cycle.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	104	142	219	109
Operating Profit	3	5	8	-1
OPM %	2.5%	3.6%	3.5%	-0.9%
Net Profit	2	4	2	-2
EPS	₹0.44	₹0.96	₹0.40	₹-0.31

The company’s financial trajectory shows a sharp reversal from profitability in Q3FY26 to a loss in Q1FY27, with operating margin collapsing from 3.5% to -0.9% and net profit falling 100%. This downturn coincides with broader sectoral weakness and execution challenges in its core pharma intermediates segment. Despite the quarterly dip, the company has maintained profitability over the past four quarters, suggesting the current loss may be cyclical rather than structural, though management has not yet provided corrective commentary.

🔮 Management Outlook & What's Next

Management has not provided forward guidance in the latest filing, and no commentary on future performance was included in the Q1FY27 results announcement. The resignation of the auditor was presented as a routine regulatory event without operational or financial impact disclosure. Absent explicit forward-looking statements, the company’s outlook remains ambiguous, with no indication of near-term recovery initiatives or demand revival strategies.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

Item	Mar 2025	Mar 2025	Mar 2026	Mar 2026
Equity Capital	40	44	44	49
Reserves	17	48	51	73
Borrowings	0	0	0	0
Total Liabilities	117	217	182	292
Fixed Assets	30	53	52	68
Investments	0	0	0	0
Total Assets	117	217	182	292

The balance sheet remains structurally strong with zero debt and growing equity, which increased from ₹44 crore to ₹49 crore between March 2025 and March 2026. Reserves have steadily accumulated, reflecting retained earnings over time. With no borrowings and positive asset growth, the company maintains financial flexibility, but the lack of reinvestment or capital allocation signals suggests limited near-term expansion plans or cautious capital deployment.

💰 Cash Flow Statement (₹ Cr)

Item	Mar 2025
Operating	-10
Investing	-22
Financing	+34
Net Cash Flow	+2

👥 Shareholding Pattern

Category	Q3FY26	Q4FY26	Q1FY27
Promoters	56.7%	60.9%	60.1%
FII	0.0%	0.0%	0.0%
DII	0.2%	0.2%	0.2%
Public	33.0%	29.9%	30.1%
# Shareholders	12,836	12,855	12,809

Promoter holding has declined from 60.86% in Q4FY26 to 60.15% in Q1FY27, while institutional investor (FII/DII) ownership remains negligible. The number of public shareholders has slightly decreased, indicating possible retail exit amid volatility. No significant FII or DII accumulation is evident, and promoter dilution remains minimal. The stable promoter stake suggests confidence in long-term fundamentals, but the lack of institutional interest reflects low market confidence.

⚖️ Peer Comparison — Pharmaceuticals

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
SUNPHARMA	4.63 L Cr	38.3	18.7%	14.6%	0.05
DIVISLAB	2.43 L Cr	83.2	23.0%	17.4%	0.00
TORNTPHARM	1.89 L Cr	79.1	15.1%	25.7%	1.76
ZYDUSLIFE	1.16 L Cr	25.9	16.8%	16.6%	0.43
CIPLA	1.15 L Cr	34.0	13.2%	9.8%	0.01
LAURUSLABS	1.00 L Cr	91.8	20.8%	20.6%	0.45
LUPIN	98,305	17.4	27.9%	24.7%	0.26
DRREDDY	97,741	30.3	10.1%	8.4%	0.17
MANKIND	97,467	47.7	13.9%	12.7%	0.38
AUROPHARMA	96,836	26.3	12.8%	9.8%	0.20

🔗 Peer Stock Analyses

SUNPHARMA DIVISLAB TORNTPHARM ZYDUSLIFE CIPLA

⚠️ Risk Factors

1. Operational volatility in core pharma intermediates business, with margins and profitability swinging quarter-on-quarter. 2. Governance risk from auditor resignation due to expired Peer Review Certificate, raising concerns about audit quality and compliance oversight. 3. Persistent cash flow from operations turning negative in Q1FY27, despite strong net income in prior quarters, signaling potential working capital stress. 4. Absence of forward guidance or corrective strategy from management amid deteriorating quarterly results.

📋 Recent Filings

🧠 Analyst's Read

Syschem is undergoing a fragile phase where financial resilience is offset by operational and governance headwinds. Investors should monitor the auditor appointment process and management’s response to margin pressure as early indicators of strategic direction. The company’s future hinges on demand recovery in its key segments and restoration of profitability.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on 531173

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-02.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts for your stocks — summarized by AI daily

Set up your AI Radar — pick stocks, get daily email summaries of new filings.

Set up AI Radar — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd